doi:10.1007/s12250-021-00436-1

[1]
Jianhui Nie, Juan Zhao, Qingqing Chen, Weijin Huang, Youchun Wang, 2014: Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12, Virologica Sinica, 29, 299-307. doi: 10.1007/s12250-014-3485-z
[2]
Weijia Cheng, Shiyou Chen, Ruiling Li, Yu Chen, Min Wang, Deyin Guo, 2015: Severe acute respiratory syndrome coronavirus protein 6 mediates ubiquitin-dependent proteosomal degradation of N-Myc (and STAT) interactor, Virologica Sinica, 30, 153-161. doi: 10.1007/s12250-015-3581-8
[3]
Jiakai Zhao, Jiahong Zhu, Ying Wang, Mengting Yang, Qiang Zhang, Chong Zhang, Yuchen Nan, En-Min Zhou, Yani Sun, Qin Zhao, 2022: A simple nanobody-based competitive ELISA to detect antibodies against African swine fever virus, Virologica Sinica, 37, 922-933. doi: 10.1016/j.virs.2022.09.004
[4]
Xinhui Zhang, Yi Liao, Xiuying Liu, Jingya Zhou, Peixiang Gao, Xuemeng Dong, Shengnan Pan, Huarui Duan, Junyu Liu, Xiaojing Chi, Wei Yang, 2026: Nanobody targeting glycan cap confers broad orthoebolavirus neutralization, Virologica Sinica, 41, 413-422. doi: 10.1016/j.virs.2026.03.018
[5]
李红霞, 孟小林*, 徐进平, 王健, 鲁伟, 曹旭, 2004: Expression of Recombinant Envelope Proteins VP19 and VP28 of WSSV and Preparation of Neutralizing Antibody, Virologica Sinica, 19, 587-590.
[6]
Ningning Ge, Jin Sun, Zhihua Liu, Jiayi Shu, Huimin Yan, Zhihua Kou, Yu Wei, Xia Jin, 2022: An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses, Virologica Sinica, 37, 266-276. doi: 10.1016/j.virs.2022.01.032
[7]
Xue-ling WU, Chun-tao ZHANG, Xiao-ke ZHU, You-chun WANG, 2010: Detection of HPV Types and Neutralizing Antibodies in Women with Genital Warts in Tianjin City, China, Virologica Sinica, 25, 8-17. doi: 10.1007/s12250-010-3078-4
[8]
Chunpeng Yang, Rui Gong, Natalia de Val, 2019: Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure, Virologica Sinica, 34, 168-174. doi: 10.1007/s12250-019-00093-5
[9]
Dezhi Li, Jie Liu, Li Zhang, Tianshu Xu, Junheng Chen, Liping Wang, Qi Zhao, 2015: N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies, Virologica Sinica, 30, 449-456. doi: 10.1007/s12250-015-3664-6
[10]
Qiuxue Han, Shen Wang, Zhenshan Wang, Cheng Zhang, Xinyue Wang, Na Feng, Tiecheng Wang, Yongkun Zhao, Hang Chi, Feihu Yan, Xianzhu Xia, 2023: Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models, Virologica Sinica, 38, 787-800. doi: 10.1016/j.virs.2023.07.003
[11]
Zhichao Yin, Yuanyuan Wu, Rui Zhu, Longfa Xu, Yu Lin, Hongwei Yang, Wenkun Fu, Qiongzi Huang, Dongqing Zhang, Jue Wang, Wei Wang, Yingbin Wang, Tong Cheng, Ningshao Xia, 2021: Development of A Neonatal Mouse Model for Coxsackievirus B1 Antiviral Evaluation, Virologica Sinica, 36, 1575-1584. doi: 10.1007/s12250-021-00444-1
[12]
Peng-cheng Yu, Akira Noguchi, Satoshi Inoue, Qing Tang, Simon Rayner, Guo-dong Liang, 2012: Comparison of RFFIT Tests with Different Standard Sera and Testing Procedures^*, Virologica Sinica, 27, 187-193. doi: 10.1007/s12250-012-3247-8
[13]
Ting Tu, Jianbo Zhan, Danlei Mou, Wei Li, Bin Su, Tong Zhang, Tao Li, Ning Li, Hao Wu, Cong Jin, Huabiao Chen, 2017: In vitro inhibition of HIV-1 replication in autologous CD4⁺ T cells indicates viral containment by multifactorial mechanisms, Virologica Sinica, 32, 485-494. doi: 10.1007/s12250-017-3992-9
[14]
Yingshuo Ma, Man Li, Lyu Xie, Na Gao, Dongying Fan, Kaihao Feng, Yao Yao, Yong Zhou, Ziyang Sheng, Hongning Zhou, Hui Chen, Jing An, 2021: Seroepidemiologic Study on Convalescent Sera from Dengue Fever Patients in Jinghong, Yunnan, Virologica Sinica.
[15]
Dan Luo, Yuanjiu Miao, Xianliang Ke, Zhongyuan Tan, Chun Hu, Penghui Li, Ting Wang, Yuan Zhang, Jianhong Sun, Yan Liu, Hanzhong Wang, Zhenhua Zheng, 2020: Baculovirus Surface Display of Zika Virus Envelope Protein Protects against Virus Challenge in Mouse Model, Virologica Sinica, 35, 637-650. doi: 10.1007/s12250-020-00238-x
[16]
Xin MA, Cai-jun SUN, Feng LI, Ling CHEN, 2007: HIV Vaccine-Challenges and Opportunities, Virologica Sinica, 22, 486-492.
[17]
马翠卿, 周育森, 王弋嘉, 郭彦, 管洁, 魏林, 何玉先, 2005: Expression and Immunogenicity Analysis of the Receptor-binding Region of SARS-CoV Spike Protein, Virologica Sinica, 20, 472-475.
[18]
Yuelin Wang, Wei Dou, Yingying Chen, Ke Liu, Mengjun Li, Tyuji Hoshino, Yushan Jiang, Vladislav Victorovich Khrustalev, Alexey V. Churov, Alexander N. Orekhov, Wei Zhao, Ling Li, Yang Yang, Chenguang Shen, 2026: Development and characterization of neutralizing monoclonal antibodies against clinically relevant human adenovirus subgroup B serotypes, Virologica Sinica, 41, 404-412. doi: 10.1016/j.virs.2026.03.017
[19]
Jizhen Wang, Balaji Manicassamy, Michael Caffrey, Lijun Rong, 2011: Characterization of the Receptor-binding Domain of Ebola Glycoprotein in Viral Entry, Virologica Sinica, 26, 156-170. doi: 10.1007/s12250-011-3194-9